

Senvelgo[®]
(velagliflozin
oral solution)

Less stress. More living.



Tested extensively, proven repeatedly

SEVELGO® (velagliflozin oral solution) is the product of an intense development process that involved years of research and large-scale field studies to ensure that it delivers both consistent glycemic control and peace of mind.



Demonstrated excellent efficacy and safety in multiple pivotal clinical field trials featuring over **300** insulin-naive, previously insulin-treated, and otherwise healthy diabetic cats¹⁻³



Cats that received SEVELGO oral solution during studies experienced **zero** clinical hypoglycemic events¹⁻³



Velagliflozin is the result of extensive research, testing and collaboration with human and animal diabetes experts at Boehringer Ingelheim



SEVELGO oral solution is supported by the Boehringer Ingelheim Technical Solutions Team, which is highly experienced in diabetes management and equipped to help you with your diabetes questions



In studies, cats on SEVELGO® (velagliflozin oral solution) enjoyed marked decreases in glycemic parameters and had fewer monitoring requirements compared to cats receiving traditional insulin treatments¹⁻³



SEVELGO oral solution is backed by the Feline Diabetes Patient Support Program, which offers a refund of the purchase price of SEVELGO oral solution, a complimentary bottle of PROZINC® (protamine zinc recombinant human insulin) and a PROZINC Care Kit at no charge if a cat is not a suitable candidate to use SEVELGO oral solution

IMPORTANT SAFETY INFORMATION: SEVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning. Cats treated with SEVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SEVELGO. Do not use SEVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus.** The use of SEVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SEVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death. Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SEVELGO should prompt immediate discontinuation of SEVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SEVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis. Keep SEVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**

IMPORTANT SAFETY INFORMATION: PROZINC® (protamine zinc recombinant human insulin) is for use in cats and dogs only. Animals presenting with severe ketoacidosis, anorexia, lethargy, and/or vomiting should be stabilized with short-acting insulin and appropriate supportive therapy until their condition is stabilized. As with all insulin products, careful patient monitoring for hypoglycemia and hyperglycemia is essential to attain and maintain adequate glycemic control and to prevent associated complications. Overdosage can result in profound hypoglycemia and death. Progestogen and glucocorticoid use should be avoided. PROZINC insulin is contraindicated in cats during episodes of hypoglycemia and in cats sensitive to protamine zinc recombinant human insulin or any other ingredients in the PROZINC product. For more information, please see enclosed full prescribing information for cats.



A life- and time- saving **solution**

SEVELGO® (velagliflozin oral solution) revolutionizes feline diabetes management with an innovative, easy-to-give, once-daily liquid oral solution.¹⁻⁴



Once-daily oral liquid solution that can be administered directly into the cat's mouth or applied onto a small amount of food²



Reduces hyperglycemia, leading to sustained glycemic control starting in as soon as 7 days³



Significantly reduces risk of clinical hypoglycemic events¹⁻³



Precise dosing tailored to the weight of the cat



Less-intensive monitoring^{2,3}



Convenient oral liquid well-accepted by most cats³



Easy storage – no refrigeration necessary before or after opening²



Backed by the Feline Diabetes Patient Support Program



**3 months' supply*
and good for 6
months after
opening**

IMPORTANT SAFETY INFORMATION: SENVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning.**

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO.

Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**

*3 months' supply for an 11-pound cat.

Fast & sustained glucose management

SEVELGO® (velagliflozin oral solution) helps alleviate the stress of feline diabetes on the cat and its owner by making noticeable improvements to symptoms, including the reduction of polyuria and polydipsia within a week of treatment.¹⁻³



IMPORTANT SAFETY INFORMATION: SENVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning.**

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO.


Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**


Fast control

Blood glucose (BG) levels begin normalizing within 7 days of beginning **SEVELGO**[®] (velagliflozin oral solution).^{1,3}



Sustained efficacy


In a study, **SEVELGO** oral solution helped diabetic cats maintain proper glucose levels over an extended period of use.³



With fast-acting and lasting efficacy from an easy-to-give, once-daily oral liquid solution, your clients and patients can get back to enjoying their lives.

How it works

SENVELGO® (velagliflozin oral solution) mode of action¹⁻⁴



- Highly selective, targeting Sodium Glucose Co-Transporter 2 (SGLT2) while sparing SGLT1
- Inhibits reabsorption of most of the glucose from the filtrate in most cats
- Promotes active glucose elimination via the urine in most cats
- Helps rapidly reverse glucose toxicity by normalizing blood glucose levels
- Resolves clinical signs of feline diabetes
- Significantly lowers the risk of clinical hypoglycemic events by inhibiting SGLT2 while minimizing the effect on SGLT1



Scan here to learn more about

SGLT2.



*See the mode of action,
in action.*



IMPORTANT SAFETY INFORMATION: SENVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning.**

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO.

Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**

Patient selection and **monitoring**

In a study, 89.1% of naive diabetic cats were a treatment success with SENVELGO® (velagliflozin oral solution) by Day 30.³ Here's how to identify which newly diagnosed diabetic cats may benefit from SENVELGO oral solution.




Stable diabetic

The cat is eating, drinking, and interactive, with no signs of vomiting, diarrhea, dehydration, lethargy or cachexia



Unstable diabetic

The cat is inappetent, vomiting, not drinking, lethargic or has diarrhea.



IMPORTANT SAFETY INFORMATION: SENVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning.**

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO.

Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**

[†] Blood ketones can also be measured, If signs of ketonuria are noted, or excessive ketonemia is identified (as defined by a blood ketone concentration exceeding the upper end of the reference interval for the ketone monitoring system/assay), evaluate for DKA/eDKA.

Beginning treatment

SEVELGO® (velagliflozin oral solution) gives you an appealing way to treat a diabetic cat while sparing your client the stress associated with twice-daily insulin administration. And with SEVELGO oral solution, dosing is weight-based, so it's accurate and precise starting from the first treatment.



1. Before starting a patient on SEVELGO oral solution, confirm that they meet the SEVELGO Patient Management Guide's requirements. The cat should be hydrated, eating drinking and not showing any signs of DKA.[†]
2. Dose the cat once-daily with the amount tailored to the cat's body weight (1 mg/kg).
3. Schedule a follow-up 2-3 days after the first dose is given, to assess, among other things, hydration, weight and body condition. Additional follow-ups should be scheduled on day 7, and optionally on day 14. It's recommended to have an additional follow-up at week 4 to further evaluate treatment efficacy and the cat's progress.
4. You may provide the cat owner with urine test strips to check for ketones between follow-up visits during the first 1-2 weeks of treatment.[§] This does not replace in-office rechecks.
5. After week 4, schedule re-checks every 3-4 months in accordance with your diabetic patient protocols. If any concerns or health changes arise, the cat should return immediately for reevaluation.



Learn more about monitoring your patients' progress.

[†] SEVELGO oral solution should not be given to a cat that has not been eating and drinking, or that appears lethargic.

[§] Blood ketones can also be used for monitoring if that is preferred.

Euglycemic diabetic ketoacidosis (eDKA)

Euglycemic diabetic ketoacidosis (eDKA) is a condition similar to diabetic ketoacidosis (DKA), only it may occur when blood glucose is within a normal range. Cats experiencing eDKA will display many of the same signs associated with DKA, and should be treated the same way.

While low, there is a risk of eDKA in cats treated with an SGLT2 inhibitor if the cat has:

- Experienced a prolonged period of time during which the diabetes mellitus went untreated
- Concurrent inflammatory or endocrine disease
- Clinical signs consistent with DKA
- Ketonemia or ketonuria

Suspend use of SENVELGO® (velagliflozin oral solution) if the patient tests positive for ketones or displays signs of DKA/eDKA.

The importance of early treatment monitoring

Nearly all eDKA episodes occurred in patients during the first 14 days on SENVELGO oral solution. At-home daily monitoring for clinical signs and urine ketones is also recommended during this time frame.^{||}

In a study,

94.9%

of cats receiving SENVELGO oral solution remained eDKA-free.³

Scan for more information about eDKA.



Screening for ketosis/DKA/eDKA

First 14 days

Day 2-3

Screened at veterinarian's office

ketones[†], glycemic control, PE, weight, clinical signs

Day 7

Screened at veterinarian's office

ketones[†], glycemic control, PE, weight, clinical signs

Day 14

Screened at veterinarian's office

ketones[†], glycemic control, PE, weight, clinical signs

Long-term

Recheck at week 4 and then every 3 months

Check ketones, glycemic control, PE, weight

If patient is unwell, evaluate for DKA/eDKA and/or concurrent disease

^{||} For additional at-home monitoring, send pet owners home with urine ketone strips.

[†] Blood ketones can also be measured. If signs of ketonuria are noted, or excessive ketonemia is identified (as defined by a blood ketone concentration exceeding the upper end of the reference interval for the ketone monitoring system/assay), evaluate for DKA/eDKA.

In the event of DKA/eDKA:



Suspend use of
SENVELGO® (velagliflozin oral solution)



Initiate short-acting insulin treatment
(even with normal glucose levels)



Supplement the cat with electrolytes
and intravenous dextrose as needed



Provide proper nutrition to prevent or
treat possible hepatic lipidosis



If you have any additional questions,
please ask your sales rep to arrange a call
with one of our feline diabetes experts

As with any treatment, there is the chance
for adverse effects. Reactions to be aware
of include:

- Diarrhea or loose stool
- Emesis
- Anorexia
- Polyuria
- Polydipsia
- Hypersalivation
- Dehydration
- Signs of DKA
- Ketones in urine



If you have any additional questions, please
contact your Boehringer Ingelheim representative.

IMPORTANT SAFETY INFORMATION: SENVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning.**

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO.

Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**

A game-changing option

SEVELGO® (velagliflozin oral solution)
is the liquid oral answer to feline diabetes.



This groundbreaking innovation, developed in a collaborative effort between Boehringer Ingelheim experts in human and feline diabetes, gives:



Cats
A new lease on life




Cat owners
The convenient, once-daily oral liquid doesn't impede on their lifestyle or daily routine



Veterinarians
A time- and cost-efficient option for treating diabetic cats that more clients will hopefully commit to⁵



90% of cat owners prefer treating their cats with
liquid solutions
instead of pills/tablets.^{6,7}



For more information, please contact your Boehringer Ingelheim representative, or scan the QR code above.



**FELINE DIABETES
PATIENT SUPPORT
PROGRAM**

The **Feline Diabetes Patient Support Program** is here to cultivate confidence in prescribing innovative, once-daily **SENVELGO**[®] (velagliflozin oral solution) for feline patients by providing the resources to foster treatment success.

If **SENVELGO** oral solution proves not to be the right option for your feline diabetic patient and **PROZINC**[®] (protamine zinc recombinant human insulin) becomes clinically necessary, Boehringer Ingelheim will support the patient's transition to **PROZINC** insulin by:

- 1 Reimbursing your clinic for its purchase price of the **SENVELGO** oral solution bottle
- 2 Providing the pet owner a complimentary first bottle of **PROZINC** insulin
- 3 Offering the pet owner a free **PROZINC** Care Kit, if requested[†]

Call Boehringer Ingelheim Veterinary Technical Solutions Team at 1-888-637-4251 with the patient information for assistance.

IMPORTANT SAFETY INFORMATION: SENVELGO[®] (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning.**

Cats treated with SENVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO.

Do not use SENVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SENVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SENVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SENVELGO should prompt immediate discontinuation of SENVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SENVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SENVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**

[†]See the Feline Diabetes Patient Support Program eligibility requirements for more information.

Once-a-day and they're on their way

Once-daily, easy-to-give **SENVELGO®** (velagliflozin oral solution) can help remove any hesitation pet owners and vets have about treating this chronic disease.

SENVELGO oral solution is a highly selective inhibitor of the SGLT2 – and it's good news for the future of diabetes management:

 <p>Helps reduce the complexity of treatment for cats, owners and veterinary practices, too</p>	 <p>Anyone on the veterinary healthcare team can train owners on how to administer SENVELGO oral solution</p>
 <p>As a once-daily solution, owners don't have to make drastic changes to their lifestyle or daily routines</p>	 <p>The less-intensive monitoring it requires gives veterinary practices more time to focus on other aspects of the cat's health^{2,3}</p>
 <p>It's an oral liquid, which is well-accepted by most cats³</p>	 <p>Extremely low risk of clinical hypoglycemic events¹⁻³</p>



**SEVELGO® (velagliflozin oral solution)
can help make more cat owners say**

yes

**to treating this manageable
disease, and enjoy a normal
quality of life while doing it.**

IMPORTANT SAFETY INFORMATION: SEVELGO® (velagliflozin oral solution) is indicated to improve glycemic control in otherwise healthy cats with diabetes mellitus not previously treated with insulin. **Before using this product, it is important to read the entire product insert, including the boxed warning.**

Cats treated with SEVELGO may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis, both of which may result in death. Development of these conditions should be treated promptly, including insulin administration and discontinuation of SEVELGO.

Do not use SEVELGO in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus. The use of SEVELGO in cats with insulin-dependent diabetes mellitus, or the withdrawal of insulin and initiation of SEVELGO, is associated with an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis and death.

Sudden onset of hyporexia/anorexia, lethargy, dehydration, or weight loss in cats receiving SEVELGO should prompt immediate discontinuation of SEVELGO and assessment for diabetic ketoacidosis, regardless of blood glucose level. SEVELGO should not be initiated in cats with ketonuria, ketonemia, pancreatitis, anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus, as it may indicate the presence of other concurrent disease and increase the risk of diabetic ketoacidosis.

Keep SEVELGO in a secure location out of reach of **children**, dogs, cats, and other animals to avoid accidental ingestion or overdose. **For more safety information, please refer to the package insert.**

References

- ¹ SENVELGO® (velagliflozin oral solution) [Freedom of Information Summary; NADA 141-568]. Duluth, GA: Boehringer Ingelheim Vetmedica, Inc.; 2023.
- ² SENVELGO® (velagliflozin oral solution) [prescribing information] Duluth, GA: Boehringer Ingelheim Animal Health USA Inc.; 2023.
- ³ Data on file at Boehringer Ingelheim.
- ⁴ Niessen et al, Once daily oral therapy for feline diabetes mellitus: SGLT2-inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats; Abstract ECVIM 2022, *J Vet Intern Med.* 2022.
- ⁵ Data on file at Boehringer Ingelheim.
- ⁶ Zimmering T. Ease of use of SEMINTRA and its effects on quality of life—update on cat owner feedback (“EASY Programme”) Poster presented at: 21st Federation of European Companion Animal Veterinary Associations (FECAVA); October 15-17, 2015; Barcelona, Spain.
- ⁷ Taylor S, Caney S, Bessant C, Gunn-Moore D. Online survey of owners’ experiences of medicating their cats at home. *J Feline Med Surg.* 2022;24:1283-1293.

Get back
to **living**



Senvelgo 
(velagliflozin
oral solution)

Senvelgo[®]
(velagliflozin
oral solution)

